Recognition marks a new chapter for the oncology-focused biotechnology company as it continues development of its investigational biologic candidate targeting mechanisms associated with cancer recurrence and treatment resistance.

Creative Biotherapeutics, LLC, led by Anita Davidson, DPT, and Dr. Don Davidson, is advancing CBT300, an investigational biologic therapeutic candidate targeting drug resistance, immune evasion, recurrence, and metastasis in cancer treatment failure.